Want to see JP:6190 full AI Analyst Report?

PhoenixBio Co., Ltd. (6190) Price & Analysis

0 Followers

6190 Stock Chart & Stats

¥484.00

¥9.00(2.79%)

At close: Jan 08 4:00 PM EST

¥484.00

¥9.00(2.79%)

Day’s Range― - ―

52-Week Range¥289.00 - ¥637.00

Previous CloseN/A

Volume3.50K

Average Volume (3M)11.12K

Market Cap

¥1.27B

Enterprise Value¥659.26M

Total Cash (Recent Filing)¥1.15B

Total Debt (Recent Filing)¥486.64M

Price to Earnings (P/E)84.8

Beta0.46

Next Earnings

Nov 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)30.80

Shares Outstanding4,076,933

10 Day Avg. Volume7,040

30 Day Avg. Volume11,116

Financial Highlights & Ratios

PEG Ratio-0.11

Price to Book (P/B)1.15

Price to Sales (P/S)1.14

P/FCF Ratio31.70

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary CRO PlatformPhoenixBio’s proprietary humanized-liver mouse platform supports specialized preclinical services across pharmacokinetics, metabolism, efficacy, and safety. This differentiated capability can deepen customer reliance and provide a durable foundation for repeat project-based work with pharmaceutical and biotechnology clients.

Strong Gross MarginA gross margin near 76% indicates that the service offering currently retains substantial value after direct costs. Combined with the return to positive earnings, this provides room to fund research capabilities, support operations, and convert renewed demand into stronger profitability if performance holds.

Improving LeverageLower leverage and a meaningful equity base improve PhoenixBio’s financial flexibility relative to its more stressed periods. A debt-to-equity ratio around 0.31 can reduce balance-sheet pressure and leave more capacity to sustain operations or invest in the platform while profitability recovers.

Bears Say

Weak Cash ConversionPositive reported earnings have not yet translated into comparable cash generation, with operating cash flow covering only a modest portion of profits. If this conversion remains weak, internally generated funds may be insufficient to support investment and operations without greater reliance on financing.

Earnings VolatilityLarge swings between profit and loss make the recent earnings rebound less reliable as a measure of normalized performance. Such volatility can complicate planning, weaken confidence in recurring earnings power, and make sustained margin improvement dependent on continued execution over several periods.

Historical Balance-sheet StressAlthough leverage has improved, PhoenixBio’s history of higher debt and negative returns shows that financial stability has not been consistently demonstrated. A future downturn or weaker operating period could therefore test the balance sheet before the recent improvement becomes firmly established.

6190 FAQ

What was PhoenixBio Co., Ltd.’s price range in the past 12 months?

PhoenixBio Co., Ltd. lowest stock price was ¥289.00 and its highest was ¥637.00 in the past 12 months.

What is PhoenixBio Co., Ltd.’s market cap?

PhoenixBio Co., Ltd.’s market cap is ¥1.27B.

When is PhoenixBio Co., Ltd.’s upcoming earnings report date?

PhoenixBio Co., Ltd.’s upcoming earnings report date is Nov 13, 2026 which is in 18 days.

How were PhoenixBio Co., Ltd.’s earnings last quarter?

PhoenixBio Co., Ltd. released its earnings results on Aug 14, 2026. The company reported -¥22.38 earnings per share for the quarter.

Is PhoenixBio Co., Ltd. overvalued?

According to Wall Street analysts PhoenixBio Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PhoenixBio Co., Ltd. pay dividends?

PhoenixBio Co., Ltd. does not currently pay dividends.

What is PhoenixBio Co., Ltd.’s EPS estimate?

PhoenixBio Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PhoenixBio Co., Ltd. have?

PhoenixBio Co., Ltd. has 4,076,933 shares outstanding.

What happened to PhoenixBio Co., Ltd.’s price movement after its last earnings report?

PhoenixBio Co., Ltd. reported an EPS of -¥22.38 in its last earnings report. Following the earnings report the stock price went down -0.284%.

Which hedge fund is a major shareholder of PhoenixBio Co., Ltd.?

Currently, no hedge funds are holding shares in JP:6190

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PhoenixBio Co., Ltd.

PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.